Story

Arm Stock Slides on Back-to-Back Cautious Analyst Calls

ENTHMSVIIDZHZH-TWJAKOHI
Jul 16, 20261 min read
Arm Stock Slides on Back-to-Back Cautious Analyst Calls

Summary

Shares of the chip designer fell sharply after analysts from HSBC and Benchmark raised concerns about the company's high valuation following its AI-driven rally. The cautious outlook comes ahead of Arm's quarterly earnings report later this month.

Text size
Background

Arm Holdings (NASDAQ: ARM) shares fell more than 5% on Tuesday, extending recent losses as investors weighed two cautious analyst reports in as many days that highlighted the chip designer's stretched valuation.

The stock was trading down 5.8% at $260.83 in morning activity, underperforming the broader tech sector.

Analyst Downgrades Drive Sentiment

The immediate pressure on Arm's stock stems from recent analyst actions that have tempered enthusiasm following a significant AI-fueled rally.

  • On July 14, an HSBC analyst downgraded Arm from "Buy" to "Hold," arguing that the stock's price already reflects much of its long-term growth potential. Despite the downgrade, HSBC raised its price target on the shares to $315 from $255.
  • The following day, Benchmark initiated coverage with a "Hold" rating, adding to a growing consensus of caution among analysts.

Both firms cited Arm's high valuation as a primary concern. The stock trades at a triple-digit trailing price-to-earnings ratio, leaving little room for disappointment in its upcoming financial results.

Sample IUX Markets – In-articleAd

Market Context and Near-Term Headwinds

The sell-off in Arm shares occurred amid wider weakness in high-growth technology stocks, with the Nasdaq Composite declining 0.6% while the Dow Jones Industrial Average remained flat. This divergence indicates a selective rotation away from names with premium valuations.

Investors are also monitoring potential near-term operational challenges. The source material noted reports of supply-chain bottlenecks for Arm's new AGI CPU, where demand from large-scale cloud providers has reportedly outstripped capacity for components. This could impact the timing of revenue recognition ahead of the company's quarterly earnings report, which is scheduled for July 29.

While Arm's fundamental long-term growth story in AI and data centers remains a key focus for investors—with data center royalty revenue more than doubling year-over-year last quarter—its current valuation makes it vulnerable to shifts in market sentiment and pre-earnings anxiety.

Read next

More on Stocks
Shenzhen-Listed Jingxin Pharmaceutical Refiles for Hong Kong IPO

Stocks

Shenzhen-Listed Jingxin Pharmaceutical Refiles for Hong Kong IPO

Sep 20, 2026

Zhejiang Jingxin Pharmaceutical Co., Ltd. (002020.SZ) has resubmitted its application for a main board listing on the Hong Kong Stock Exchange, aiming to secure a dual listing to access international capital. The company specializes in drugs for central nervous system and cardiovascular diseases.

Back to latest news

LATEST